ABBV Jan 2025 170.000 call
| Previous close | 8.74 |
| Open | 8.75 |
| Bid | 9.75 |
| Ask | 10.10 |
| Strike | 170.00 |
| Expiry date | 2025-01-17 |
| Day's range | 8.75 - 8.75 |
| Contract range | N/A |
| Volume | |
| Open interest | 4.22k |
PR NewswireAbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian Cancer
AbbVie (NYSE: ABBV) announced today positive topline results from the Phase 2 PICCOLO trial evaluating investigational mirvetuximab soravtansine (ELAHERE®) monotherapy in heavily pre-treated patients with folate receptor-alpha (FRα) positive, platinum-sensitive ovarian cancer (PSOC). The study met its primary endpoint with an objective response rate (ORR) of 51.9% (95%CI 40.4 – 63.3%).
PR NewswireSkinMedica® Celebrates 25 Years of Empowering Radiant Skin
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), the makers of BOTOX® Cosmetic (onabotulinumtoxinA), is celebrating 25 years of SkinMedica®. To mark this milestone anniversary, Allē Members who purchase SkinMedica® products at a participating Allē Health Care Provider or SkinMedica.com from June 1 to June 25, 2024 can earn double points* and enter for a chance to win $5,000.**
- PR Newswire
AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers
AbbVie (NYSE: ABBV) today launched the AbbVie Migraine Career Catalyst AwardTM, a first-of-its-kind contest designed to support the career, workplace, and professional development aspirations of people living with migraine. With more than 113 million workdays lost in the U.S. each year to the disease and its symptoms, migraine can have a major impact in the workplace.1 Twenty contest entrants will win up to $2,500 that they can decide to use toward career support, including career counseling, pr
